Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ourense
Clinical trial register · Spain

Clinical Trials in Ourense, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca7 Daiichi Sankyo4 AbbVie3 Pfizer2 Bristol-Myers Squibb2
Site location
Barcelona3238 Madrid3046 Valencia1215 Seville1054 Málaga746
All 453 locations
Target enrolment
to

Trials with a site in Ourense

52 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Not yet open
Optical Diagnosis of Neoplasia Using Artificial Intelligence
NCT07158203Polyps Colorectal, Colonoscopy, Optical Biopsy, Colorectal Cancer Control and Prevention
Fundacin Biomedica Galicia Sur
Not applicable
70
Ourense
2026-10
Not yet open
Gruppo Oncologico del Nord-Ovest
Phase 3
244
Barcelona, Madrid, Málaga, Ourense, Pamplona, Santander, Valencia, Zaragoza
2026-09-01
Not yet open
Vall d'Hebron Institute of Oncology
Phase 2
150
Córdoba, Zaragoza, Santander, Barcelona, L'Hospitalet de Llobregat, Sabadell, Lugo, Ourense
2026-06
Recruiting
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
DrugsPF-08634404·Nivolumab
Pfizer
Phase 2/3
840
Barcelona, Madrid, Ourense
2026-05-14
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
150
Barcelona, Córdoba, Lleida, Madrid, Ourense, Sant Cugat del Vallès
2026-04-16
Not yet open
University Hospital, Toulouse
Observational
209
Alicante, Ourense, Pamplona
2026-04-01
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
Granada, Ourense
2026-03-12
Recruiting
Janssen Research & Development, LLC
Observational
380
Córdoba, Jerez de la Frontera, Lugo, Málaga, Ourense, Palma de Mallorca, Santiago de Compostela, Seville
2025-12-03
Recruiting
Sanofi
Phase 3
980
Ourense, Gijón, Huelva, Madrid
2025-10-01
Recruiting
AstraZeneca
Phase 2
100
Barcelona, Elche, Madrid, Málaga, Ourense, Oviedo, Santander, Valencia
2025-07-17
Recruiting
GlaxoSmithKline
Phase 2
80
Barcelona, Madrid, Málaga, Ourense, PamplonaNavarra, Salamanca, Valencia
2025-06-05
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Santiago de Compostela, Gijón, Lugo, Madrid, Ourense, Seville
2025-05-27
Active, closed
VITUS Post-Market Registry
NCT06832631Peripheral Arterial Disease, Peripheral Arterial Occlusive Disease
OrbusNeich
Observational
283
Gijón, Granollers, Ourense, Toledo
2025-05-22
Recruiting
Daiichi Sankyo
Phase 3
510
Burgos, Elche, L'Hospitalet de Llobregat, Madrid, Málaga, Ourense, Oviedo, Pamplona
2025-03-27
Recruiting
AstraZeneca
Phase 3
840
Badalona, Barcelona, Madrid, Ourense, Santander, Seville, Valencia
2025-03-01
Active, closed
AbbVie
Phase 2
185
Pamplona, Madrid, Ourense, Valencia
2024-12-13
Recruiting
Diego Matías Domínguez Prado
Not applicable
314
Monforte de Lemos, Verín, Vigo, Vilagarcía de Arousa, Ourense, Pontevedra
2024-09-30
Recruiting
Prospective Observational Study to Evaluate the Safety of Immunotherapy as a Treatment for Hymenoptera Venom Allergy
NCT06782217Allergy, Insect Venom, Allergy Insect Stinging, Insect Sting Allergy
DrugVenox
Inmunotek S.L.
Observational
120
Ferrol, Plasencia, Burela de Cabo, Monforte de Lemos, A Coruña, Barcelona, Lugo, Ourense
2024-09-01
Active, closed
AbbVie
Phase 3
421
Badalona, Ourense, León, Madrid, Salamanca, Valencia
2024-05-19
Active, closed
Samsung Bioepis Co., Ltd.
Phase 3
555
Leganés, Málaga, Ourense, Oviedo, Santiago de Compostela, Seville, Valencia
2024-03-12
Active, closed
AstraZeneca
Phase 3
594
Barcelona, Madrid, Ourense, Santander, Seville
2024-03-04
By invitation
Surveillance of Suicide Ideation in Adolescents (VISIA)
NCT06341634Suicide, Distress, Emotional, Adolescent Behavior, Healthy
Servicio Gallego de Salud
Observational
339
Santiago de Compostela, Vigo, Ourense
2024-02-06
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Jerez de la Frontera, Madrid, Ourense, Valencia, Lugo, Seville
2023-12-31
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Santiago de Compostela, Zaragoza, Poniente Sur, Santander, Burgos, Ourense, Majadahonda, El Palmar
2023-12-20
Active, closed
Bristol-Myers Squibb
Phase 3
106
L'Hospitalet de Llobregat, Barcelona, Granada, Madrid, Ourense, Salamanca, Valencia
2023-10-05
Recruiting
ADVANCED MARKER DISCOVERY S.L.
Observational
250
Málaga, Oviedo, Ourense, Madrid
2023-04-17
Active, closed
Daiichi Sankyo
Phase 3
1,170
Barcelona, Lleida, Madrid, Málaga, Ourense, Seville, Valenica, Zaragoza
2023-01-11
Active, closed
Bristol-Myers Squibb
Phase 2/3
230
Valencia, Granada, Madrid, Ourense, Oviedo, Salamanca
2022-12-14
Recruiting
AstraZeneca
Phase 3
3,527
Barcelona, Madrid, Majadahonda, Málaga, Ourense, Palma de Mallorca, Pamplona, Santander
2022-12-13
Active, closed
AstraZeneca
Phase 3
594
A Coruña, Barcelona, Castellon, Córdoba, Hospitalet deLlobregat, Madrid, Málaga, Ourense
2022-09-15
Active, closed
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
NCT05403385Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
DrugsPemetrexed·Carboplatin
iTeos Therapeutics
Phase 2
36
Palma de Mallorca, Pamplona, Valencia, A Coruña, Badajoz, Barcelona, Manresa, Ourense
2022-08-26
Recruiting
Octapharma
Phase 3
38
Oviedo, Madrid, Murcia, Ourense
2022-07-01
Active, closed
Fundacin Biomedica Galicia Sur
Not applicable
3,788
Ourense
2022-06-01
Active, closed
Daiichi Sankyo
Phase 3
740
Barcelona, Lleida, Madrid, Málaga, Ourense, Seville, Valencia, Zaragoza
2022-03-04
Recruiting
EDUARDO ALBENIZ
Observational
1,200
Palma de Mallorca, Porto Cristo, Granollers, Terrassa, Aranda de Duero, Mérida, Ourense, Majadahonda
2021-09-09
Active, closed
University Hospital A Coruña
Observational
82
Ferrol, Santiago de Compostela, Vigo, A Coruña, Lugo, Ourense, Pontevedra
2021-04-20
Active, closed
Daiichi Sankyo
Phase 3
605
Barcelona, Madrid, Málaga, Ourense, Seville, Valencia, Zaragoza
2020-12-21
Active, closed
AstraZeneca
Phase 3
957
Barcelona, Madrid, Málaga, Ourense, Santander, Seville, Valencia
2020-11-17
Recruiting
Institut Cancerologie de l'Ouest
Observational
300
Cadiz, Cartagena, Granada, Ourense, Seville, Valencia
2020-07-10
Active, closed
Amgen
Phase 3
145
Granada, Seville, Salamanca, Barcelona, Ourense, Fuenlabrada, Castellon, Madrid
2020-02-26
Active, closed
CStone Pharmaceuticals
Phase 3
534
A Coruña, Ourense, Majadahonda, Oviedo, Ávila, Barcelona, Burgos, Girona
2019-12-13
Active, closed
Spanish Oncology Genito-Urinary Group
Phase 2
39
Manresa, Sabadell, Reus, Granada, Lugo, Madrid, Ourense, Oviedo
2019-09-18
Recruiting
Treatment of Hypertension During Sleep
NCT03457168Hypertension, Hypertension, Systolic
University of Vigo
Not applicable
5,320
Ourense, A Estrada, Nigrán, Vigo, Vilagarcía de Arousa
2019-02-01
Active, closed
Celgene
Phase 3
363
Barcelona, Granada, Madrid, Málaga, Murcia, Ourense, Oviedo, Palma de Mallorca
2019-01-02
Active, closed
AbbVie
Phase 3
265
Palma de Mallorca, Marbella, Ourense, San Cristóbal de La Laguna, Barcelona, Girona, León, Madrid
2018-10-22
Active, closed
Marc van Sambeek
Observational
156
Madrid, Ourense
2018-09-11
Active, closed
Gilead Sciences
Phase 2
502
Badalona, Barcelona, Córdoba, Las Palmas, Madrid, Majadahonda, Manresa, Ourense
2018-08-13
Active, closed
Janssen Research & Development, LLC
Phase 1/2
125
Barcelona, Madrid, Málaga, Ourense, Pontevedra, Pozuelo de Alarcón, Sabadell, Santander
2018-04-05
Recruiting
UMC Utrecht
Phase 3
20,000
Barcelona, Cadiz, Córdoba, Madrid, Málaga, Ourense, Santander, Tortosa
2016-04-11
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsLupron·Eligard·Leuprorelin·Xtandi
Pfizer
Phase 3
1,068
Palma de Mallorca, Manresa, Santiago de Compostela, Barcelona, Cadiz, Girona, Madrid, Ourense
2014-12-17
Recruiting
Patient Retrospective Outcomes (PRO)
NCT01550575Chronic Pain
Boston Scientific Corporation
Observational
15,000
Barcelona, Cadiz, Cartagena, Las Palmas, Logroño, Madrid, Majadahonda, Ourense
2012-04-03
Active, closed
University of Vigo
Phase 4
3,200
Friol, Lugo, Ourense, A Estrada, Baiona, Bueu, La Guardia, Nigrán
2008-10
Rows per page Showing 1–52 of 52
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/ourense

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 52 of those studies with a site in Ourense.

How many clinical trials are recruiting in Ourense?

22 of the 52 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 4 have not yet opened recruitment, 25 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ourense), 52 studies
PhaseStudiesRecruitingShare
Phase 323844.2%
Observational12723.1%
Phase 29417.3%
Not applicable427.7%
Phase 2/3213.8%
Phase 1/2101.9%
Phase 4101.9%

Most active sponsors

Lead sponsors with the most studies (Ourense)
Lead sponsorStudiesRecruiting
AstraZeneca74
Daiichi Sankyo41
AbbVie30
Bristol-Myers Squibb20
Fundacin Biomedica Galicia Sur20
Janssen Research & Development, LLC21
Pfizer21
University of Vigo21
ADVANCED MARKER DISCOVERY S.L.11
Amgen10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.